Authors: Neer, RM Arnaud, CD Zanchetta, JR Prince, R Gaich, GA Reginster, JY Hodsman, AB Eriksen, EF Ish-Shalom, S Genant, HK Wang, OH Mitlak, BH

Citation: Rm. Neer et al., Effect of parathyroid hormone (1-34) on fractures and bone mineral densityin postmenopausal women with osteoporosis., N ENG J MED, 344(19), 2001, pp. 1434-1441

Authors: Johnston, CC Bjarnason, NH Cohen, FJ Shah, A Lindsay, R Mitlak, BH Huster, W Draper, MW Harper, KD Heath, H Gennari, C Christiansen, C Arnaud, CD Delmas, PD

Citation: Cc. Johnston et al., Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women - Three-year data from 2double-blind, randomized, placebo-controlled trials, ARCH IN MED, 160(22), 2000, pp. 3444-3450

Authors: Ettinger, B Black, DM Mitlak, BH Knickerbocker, RK Nickelsen, T Genant, HK Christiansen, C Delmas, PD Zanchetta, JR Stakkestad, J Gluer, CC Krueger, K Cohen, FJ Eckert, S Ensrud, KE Avioli, LV Lips, P Cummings, SR

Citation: B. Ettinger et al., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - Results from a 3-year randomized clinical trial, J AM MED A, 282(7), 1999, pp. 637-645

Authors: Mitlak, BH Cohen, FJ

Citation: Bh. Mitlak et Fj. Cohen, Selective estrogen receptor modulators - A look ahead, DRUGS, 57(5), 1999, pp. 653-663